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Introduction 
The cancers have been detected in early stage due to the development and widespreading of cancer 
screening  on the world , despite it is the second largest cause of mortality in the world. 
1.Objective  
The aim of my research is to show that the HPV DNA determination as a diagnostic method to 
improve significantly the effectiveness of cervical screening  and could reduce the number of surgical 
procedure done on cervix. Could determination of HPV genotyping and mapping of the prevalence of 
HPV types  of cervical cancer and precancerous cases influence the screening strategy? During my 
research, I would like to clarify which and what kind of frequency of HPV DNA can be detected in 
abnormal cytology and histological samples.  How can  the persistent HPV infection detected after 
conisation influence the prognosis of the disease? 
2. Materials and Methods  
Materials and Methods 1. 
These are the first, multicentric, retrospective parallel studies to estimate HPV type prevalence in more 
than 6000 women diagnosed with either HG-CIN or ICC across 17 European countries, using 
standardised and validated methods for specimen preparation, with centralised pathology review and 
HPV DNA testing (HERACLES-SCALE study).  Prevalence ratios of specific HPV types in ICC versus 
HG-CIN and the median age of HG-CIN and ICC diagnoses for different HPV types were estimated. 
Centralised expert histopathological review and standardised HPV DNA typing for 14 HR-HPV types 
were applied to more than 6000 parallel samples of HG-CIN and ICC. The pooled prevalence of 
individual HPV types was estimated using meta-analytic method to control for heterogeneity observed 
among the countries. For each participating country, samples were collected from consecutive 
archived formalin-fixed paraffin-embedded cervical specimens of HG-CIN or ICC from women (aged 
≥18 years) who had been diagnosed between 2001 and 2008. Information about age at diagnosis, 
year of diagnosis, and original histological diagnosis was obtained.  The majority of these sites were 
part of a cervical screening programme that had stored specimens representative of the total 
population.In each participating country, only study sites which maintained an archive of cervical 
excision specimens were selected. The majority of these sites were part of a cervical screening 
programme that had stored specimens representative of the total population. From each participating 
country, consecutive archived formalin-fixed paraffin-embedded cervical specimens of HG-CIN and/or 
ICC diagnosed between 2001 and 2008 were selected. The selection procedures were standardised. 
If several specimens were available for a subject, the most recent paraffin block containing the area 
with the highest grade of CIN or the primary ICC obtained prior to chemo/radiotherapy, was selected. 
Information about age at specimen collection, year of specimen collection, and original histological 
diagnosis were obtained. A convenient sample of 290 HG-CIN and 290 ICC were collected for each 
country, starting with the most recent specimen and dating back until reaching their respective case 
numbers. Inclusion criteria into the study (Screened Cohort) were a pathological confirmation of HG-
CIN or ICC with the availability of a cervical/excision specimen at the country level. If several 
specimens were available for a subject, the most recent paraffin block containing the area with the 
highest grade of CIN or the primary invasive cancer, obtained prior to chemo/radiotherapy, was 
selected.Reasons for exclusion from the Total cohort were that the specimen blocks were too large 
(>2cm diameter), too thin (<2mm), held highly irregular tissue, had been inadequately preserved (in 
terms of paraffin conditions) or were too worn down to cut into sections. Specimens for which 
histological examination of sections failed to confirm the same grade or type of abnormality as the 
section cut for PCR analysis and/or inability to perform HPV PCR testing were rejected from the 
Histologically-eligible cohort . 
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Laboratory procedures 
Following anonymisation, specimens were shipped to a central laboratory (DDL Diagnostic Laboratory, 
Voorburg, The Netherlands) for histopathology review and HPV-DNA detection and typing.  
At DDL the tissue blocks were sectioned and analysed according to the sandwich cutting procedure 
which ensured that PCR for HPV was performed within a sandwich of histology diagnosis.H&E 
sections were examined by an experienced gynaecological histopathologist, blinded to the initial 
diagnosis and HPV status, to confirm presence of the lesion in the section used for HPV testing. When 
multiple areas of abnormality were present in one slide, the worst grade of lesion diagnosed 
represented the study clinical diagnosis. 
Cervical samples with a confirmed histopathological diagnosis were tested for HPV using PCR 
methodology, SPF10-DEIA/LiPA25-PCR system (SPF10-LiPA25)(version 1, Laboratory Biomedical 
Products, Rijswijk, Netherlands) The SPF10-PCR primer set amplifies a small fragment of 65 bp from 
the L1 region of at least 54 HPV genotypes, as described earlier  .DEIA positive SPF10-amplifiers were 
used to identify the HPV genotype by reverse hybridisation probe assay (SPF10-LiPA25) which 
detected 25 HR and low risk (LR) HPV types (6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 
52, 53, 54, 56, 58, 59, 66, 68/73, 70, and 74).  
Statistical analysis 
The primary population for analysis was the Histologically-eligible HPV+ cohort comprising women 
with a validated diagnosis of HG-CIN or ICC and positive HPV PCR test .  From each country, 290 
women with an initial diagnosis of HG-CIN and 290 women with an initial diagnosis ICC (with 260 of 
these being SCC) were enrolled to reach the target of 210 HPV-positive women in each study allowing 
for histological misclassification and a proportion of HPV-negative cases. Sample size calculations 
demonstrated that with 210 HPV-positive women the precision of the 95% confidence interval (CI) of 
percentages for each HPV type would not exceed 6% when percentages are lower than 20% and 5% 
when percentages are lower than 10%. Data were summarised by means, medians, standard 
deviations and range for continuous variables, and by frequency and percentages for categorical 
variables. Two-sided 95% confidence intervals (95%CIs) for percentages were computed using either 
Chi-square or an exact method based on the binomial distribution (Clopper-Pearson method 
[Newcombe 1998]). Cochran Q statistics were computed to test potential differences among countries 
with respect to the proportion of each HPV type, at 5% significance level. All statistical analyses were 
performed using SAS software (version 9.1). 
 
Material and Methods 2.  
 The aim of our study was to evaluate the HPV DNA detection could decrease the number of the 
reconisation.  438 cervical conisation was done, aged 22-65 year, from March 2008 to Augustus 2010   
The indication of the procedure was citological abnormality mostly. In every cases loop electrosurgical 
procedure (LLETZ) was used. Before the cone biopsy a HPV test was taken from the cervical canal 
and the surface of cervix. HPV samples were analysed by Genoid ELISA-PCR method.  
In every cases loop electrosurgical procedure (LEEP) was used.  
LEEP conisation was performed under local anesthaesia using wire loop electrodes, with diathermy 
apparatus set to 50 W for cutting and 50 W for coagulation. Generally only one specimen  was 
removed by a single excision. All specimens were fixed with 10 % buffered formalin and submitted to 
histopathology examination.  Prior to the biopsy an HPV test was taken from the cervical canal and 
from the surface of the cervix. HPV samples were analysed by Genoid ELISA-PCR method. Spectrum 
HPV Detection Kit (Genoid) was used according to the instruction manual. The cervical specimen was 
collected in PreservCyt medium, transferred to the laboratory and after the isolation of the nucleic 
acids by silica based method a multiple HPV specific PCR was carried out. The amplicon is genotyped 
using hybridisation based method the biotinilíted amplicons were captured on solid phase and labelled 
genotype specific oligonucleotides were used as probes. The assay is capable to detect virtually all 
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mucosal HPV types and  high-risk genotypes, too (16,18,31,33,45,51,52,56,58,66,68). Pathological 
examination  verified the histological grade.. The formalin fixed preparations were sliced and 
embedded in paraffin for histological examination. The sections were stained with hematoxylin and 
eosin. The aim of our study was to assess the second (pre-reconisation) HPV test an appropriate 
method to reduce the number of interventions in histologically positive cases. 
The indication of the second LLETZ was CIN2/3 cases with positive surgical margins, accepted by the 
hungarian and international protocols.  In  all CIN1 cases we have choosen conservative treatment 
independently the status of surgical margins.  The HPV DNA detection was performed from the 
operation area before the second LLETZ in every cases.  
The statistical analysis of the data was performed according to the Chi-square test. A P value of < 
0.05 was considered significant. 
 
3.Results  
3.1 Results 1. 
For 3103 women and 3162 women in the Histologically-eligible cohorts, the diagnoses of HG-CIN and 
ICC were, respectively, confirmed and HPV testing was performed.  Among women diagnosed with 
HG-CIN, CIN3, CIN2, CIN2/3, AIS and ‘other’ accounted for 73.6%, 15.3%, 9.4%, 0.7% and 0.9% of 
cases, respectively. Among women diagnosed with ICC, SCC, ADC and ‘other’ accounted for 77.7%, 
13.4% and 8.9% respectively (Table 1). 
Table 1: HERACLES (HG-CIN) and SCALE (ICC) cohort demographics. 
 All countries Countries participating 
in both studies only 
 
Cohort 
 HERACLES 
(HG-CIN) 
SCALE 
(ICC) 
HERACLES 
(HG-CIN) 
SCALE 
(ICC) 
Total 
enrolled 
cohort 
N 
Median age (range) at 
date of specimen 
collection, years  
3979 
35 (18–86)  
3626  
48 (18–99)  
1923 
35 (18–86) 
2140 
50 (20–99) 
Histologic
ally-
eligible 
cohort 
N  
Median age (range) at 
date of specimen 
collection, years 
Main diagnosis % (HPV 
positivity rate %) 
      CIN2 
      CIN3 
      CIN2/3 
      AIS 
      SCC 
      ADC 
      Other 
3103 
34 (18–86) 
 
 
 
15·3 (95.0) 
73·6 (99.3) 
9·4 (99.3)  
0·7 (100) 
 
 
0·9 (89·3) 
 
3162 
49 (19–99) 
 
 
 
 
 
 
 
77·7 (94.2) 
13·4 (81.3) 
8·9 (86.9)  
 
1923 
35 (18–86) 
 
 
 
16·0 (94.1) 
72·0 (99.1) 
10·0 (99.0) 
0·9 (100) 
 
 
1·1 (90.0) 
 
2138 
50 (20–99)  
 
 
 
 
 
 
 
78·3 (94.3) 
13·4 (81.9) 
8·3 (86.4)  
 
HPV+ 
cohort 
N  
Median age (range) at 
date of specimen 
collection, years 
Single HPV infection % 
Multiple HPV infection % 
Unknown HPV type % 
 
3057 
34 (18–86)  
 
 
80.0 
17.4 
2.6 
 
2903 
48 (19–99) 
 
 
93.5 
4.8 
1.7 
 
1889 
35 (18–86) 
 
 
80.4 
16.9 
2.7 
 
1966 
49 (20–99) 
 
 
93.5 
4.5 
2.0 
 
5 
 
The age distribution of women in the two groups was reflected in the well-known fact that the HG-CIN 
group of mostly 26-30 years of age, and  in the  eldery age the  number of precancerous cases are 
reduced. In contrast in ICC group with increasing age the number of inavsive cases are increased. 
Median age (range) at the time of specimen collection was 34 years (18-86) for HG-CIN (33 years (19-
84) for CIN2, 34 years (18-86) for CIN3, 36 years (19-77) for CIN23 and 35 years (22-55) for AIS), and 
49 years (19-99) for ICC (45 years (22-90) for ADC and 50 years (19-99) for SCC).  
1.5% of women diagnosed with HG-CIN and 8.1% of women diagnosed with ICC were HPV negative. 
The number of women diagnosed with HPV negative (HPV−) ICC increased with increasing age, 
reaching the highest number in women aged >61 years (45.6%). Multiple HPV infections occurred in 
17.1% of HG-CIN and 4.4% in ICC diagnoses. They were more frequently observed in younger 
women with HG-CIN, decreasing in frequency with increasing age.  
The HPV+ cohorts included 3057 (98.5%) women with HG-CIN and 2903 (91.8%) women with ICC. 
2445 (80%) HPV+ women with HG-CIN and 2715 (93.5%) HPV+ women with ICC were infected with a 
single HPV type. In women infected with a single HPV type and diagnosed with HG-CIN, the most 
common types were HPV16 (59.9%), HPV33 (10.5%), HPV31 (9.0%), HPV52 (3.9%) and HPV18 
(3.6%).  
In women infected with a single HPV type and diagnosed with ICC lesions, the most common types 
were HPV16 (63.3%), HPV18 (15.2%), HPV45 (5.3%), HPV33 (4.6%) and HPV31 (3.7%).  
In women infected with a single HPV type, the pooled prevalence of LR-HPV types was 0.65% (95% 
CI: 0.00-3.63) in HG-CIN and 0.73% (0.00-4.30) in ICC. 
In each country studied, HPV16 was the most common type to be associated with both HG-CIN and 
ICC in women infected with a single HPV type. The prevalence varied from 47.1% in Norway to 71.9% 
in Estonia for HG-CIN, and from 54.4% in Norway to 72.8% in Poland for ICC. Similar variations 
across the countries were observed for HPV18/31/33/45 and ‘other’ types. 
Patterns of age-specific HPV prevalence differed between HG-CIN and ICC. This pattern was also 
observed for women with single HPV16/31/33-related HG-CIN and ICC diagnoses.  
In contrast, the highest number of women with single HPV18-related HG-CIN and ICC diagnoses was 
observed in the 31-35y age group (24.4%) and in the 51-60y groups (19.3%), respectively, showing 
that there is less time between diagnoses of HPV18-related HG-CIN and ICC than for those related to 
HPV16/31/33. A similar pattern, as for HPV18-related HG-CIN and ICC, was observed for women 
diagnosed with HPV45-related HG-CIN and ICC (26-30y (22.2%) for HG-CIN; 51-60y (20.4%) for 
ICC). 
In the 534 women infected with multiple HPV types and diagnosed with HG-CIN, the most frequent 
HPV types were HPV16 (59.9% [55.6-64.1]), HPV31 (26.0% [22.4-30.0]), HPV52 (23.4% [19.9-27.2]), 
HPV33 (18.0% [14.8-21.5]), HPV51 (15.0% [12.1-18.3]) and HPV18 (14.2% [11.4-17.5]).  
In the 138 women infected with multiple HPV types and diagnosed with ICC, the most frequent HPV 
types were HPV16 (52.9% [44.4-61.4]), HPV18 (26.8% [19.6-35.0]), HPV52 (21.0% [14.5-28.8]), 
HPV31 (19.6% [13.3-27.2]), HPV45 (18.8% [12.7-26.4]) and HPV33 (17.4% [11.5-24.8]).  
In the eight countries participating in both HERACLES and SCALE studies, the total number of women 
diagnosed with HG-CIN and ICC and included in the Histologically-eligible cohorts was 1923 and 
2138, respectively. The demographic and clinical characteristics of these two populations were similar 
to those in the overall population in the respective studies. The frequencies of HPV types in HG-CIN 
and ICC were also similar to those seen in the overall population. 
In women infected with a single HPV type, the ICC/HG-CIN prevalence ratio varied for individual HPV 
types. HPV39/18/45 were 4.8/3.5/2.5 times more prevalent in ICC than HG-CIN, respectively. HPV16 
was prevalent in both ICC and HG-CIN with a prevalence ratio of 1.1, while HPV31/33/35/52 were 
0.4/0.4/0.5/0.5 were less prevalent in ICC than HG-CIN respectively  
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The median age at diagnosis varied according to HPV type, with CIN3 being diagnosed earlier in 
women infected with HPV16 (34y), HPV31 (33y) and HPV33 (35y), and at a later median age in 
women with HPV18 (38y) and HPV45 (42y). In contrast, SCC tended to be diagnosed earlier in 
women infected with HPV16 (49y), HPV18 (47y) or HPV45 (43y) and at later age in women infected 
with HPV31, HPV33 and ‘other’ HPV types. 
 The difference in age at specimen collection between CIN3 and SCC for HPV18 (9y) was statistically 
significantly narrower when compared to the difference in age at specimen collection for HPV31 (23y), 
HPV33 (20y) and ‘other’ (17y) (p-values of <0.001, 0.001 and 0.011, respectively) and the difference 
in age at specimen collection between CIN3 and SCC for HPV45 (1y) was statistically significantly 
narrower when compared to the difference in age at specimen collection for HPV16 (15y), HPV31 
(23y), HPV33 (20y) and ‘other’ (17y) (p-values of 0.005, <0.001, <0.001 and 0.001, respectively). The 
difference, though not statistically significant, in age at specimen collection between AIS and ADC for 
HPV18 (6y) was lower than for HPV16 (13y) (p = 0.162). 
3.2 Results 2. 
The results in the second clinical trial was the next. 
119 (27,2 %) out of  438 cases were reconisations.  The indication of the second conisation was 
positive surgical margins at the first conisation in every case.  The second loop conisation was 
performed 8 weeks later after first conisation. Median age was 34.7 y(22 y-65 y). Respect to the 
median age the patients were divided to two subgroups, younger or older than 35 years. 
In 90 cases of the 119 reconisated patients (75,6 % of the total amount of reconisated patients)  
residual dysplasia was not detected at reconisation in spite of the surgical margins positivity of the first 
biopsy. 
In 77 out of this 90 patient cohort the repeated HPV test did not confirm any HPV infection.  In 13 out 
of this 90 patients HPV infection was detected repeatedly but only in 3 cases could we confirm the 
same HPV type. In this 3 cases the first histology proved severe cervical dysplasia. 
In most of  these  13 a new HPV type was detected at the pre-reconisation HPV test, showing the 
break of continuity of the persistent infection relating to previosuly detected HPV type.   
 In cases of histologically proven residual dysplasia (29 of 119) high-risk HPV infection was detected 
by HPV test, too.  
In 29 patients  ( 25,4 % of the total amount of reconisated patients), where  residual dysplasia was 
confirmed high risk HPV infection was detected by 100 %. 
Where the histology revealed persistent high grade CIN the repeated HPV test detected the same 
HPV type as occured at first time.(64%)  
Futhermore in those cases where reconisation detected lower grade of dysplasia as seen previously, a 
new HR-HPV  type was observed (38%) 
Analyzing the HPV distribution we realized that HPV 16, 31 and 33 types were very common ( 92 %) 
in precancerous lesions. .  There was no significant difference in occurrence of residual dysplasia 
between the two subgroups (below and above 35 years) by chi-square test (P<0,01). 
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4. Summary 
HPV was identified in 98·5% of HG-CIN and 91·8% of ICC specimens. The most common single-type 
HPV in HG-CIN and ICC following meta-analysis were HPV16/33/31 (59·9%/10·5%/9·0%) and 
HPV16/18/45 (63·3%/15·2%/5·3%).  We have found strongly difference of prevalence of HPV between 
SCC and ADC cases.  In SCC cases  HPV16/18/33 (66.2%/10.8%/5.3%),  in ADC cases  
HPV16/18/45 (54.2%/40.4%/8.3%) were indentified.  HPV16/18/45 were 1.1/3.5/2.5  times more 
strongly associated with ICC than HG-CIN. 
 Consistent with other studies, we found that HPV16 was the most frequent type detected across 
Europe in both HG-CIN and ICC. Women with HPV16/18/45 infection in ICC were younger than 
women with other HPV types in ICC, and those with HPV18/45 infection in CIN3 were older than those 
with other HPV types in CIN3.   
The higher prevalences of HPV18 and HPV45 in ADC compared to SCC are consistent with other 
recent data,
 
and suggest that these HPV types may differ from HPV16 in their target cell specificity. 
Hence, HPV16 infection results in predominantly squamous cervical neoplasia, while HPV18 and 
HPV45 have a greater tendency to induce glandular cervical neoplasia. 
Margin positivity was the obvious indication for reconisation in CIN3 cases.   
In our study we have performed, that second- pre-reconisation- HPV DNA test can influence our 
therapeutic decision. In those cases, where the second HPV test did not confirm   any HR-HPV 
infection, the reconisation is unnecessary procedure because the low risk of the residual severe 
dysplasia. In those cases, where the second HPV test confirmed the same HPV infection, than at the 
first one, the reconisation is confirmed because of the high risk of the severe residual dysplasia.  The 
type specific HPV detection has strongly impact in this clinical trial. The same HPV type, detected 
before the first conisation and positive surgical margins are together the indicators of reconisation. 
  According to our experience of these two clinical trial the type specific HPV detection has strongly 
impact and performing in cervical screening program is valuable for therapeutic and follow up 
procedure due to having an excellent prognostic ability.  
5. Conclusion 
These are the first parallel studies to estimate HPV type prevalence in more than 6000 women 
diagnosed with either HG-CIN or ICC across 17 European countries, using standardised and validated 
methods for specimen preparation, with centralised pathology review and HPV DNA testing. The 
pooled prevalence of individual HPV types was estimated using meta-analytic method to control for 
heterogeneity observed among the countries. A comparison of age at diagnosis for different HPV 
types was undertaken to investigate type-specific age distributions of HPV-associated HG-CIN and 
ICC. Consistent with other studies, we found that HPV16 was the most frequent type detected across 
Europe in both HG-CIN and ICC. HPV16/18/45/39/59/68 were more frequently detected in women 
diagnosed with ICC than HG-CIN; whereas HPV31/33/35/51/52/58/66 were more frequently detected 
in women diagnosed with HG-CIN than ICC. 
This is in keeping with the results of other studies of type-specific HPV prevalence across the 
spectrum of HPV-related cervical diagnoses 
Our studies also aimed to determine the prevalence ratios of specific HPV types in ICC compared to 
HG-CIN in Europe. In women infected with a single HPV type, the prevalence ratios of HPV39/18/45 in 
ICC versus HG-CIN were >1.  This observation has paid attention to intensive carcinogenetic ability of 
above mentioned HPV types. This is especially the case for ADC, which is more likely to be missed by 
screening, and for which the precursor of AIS is infrequent.  In contrast the prevalence ratios of 
HPV31/33/35/52 in ICC versus HG-CIN were ≤1, reflecting their importance in HG-CIN and a lesser 
role in ICC. 
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In addition to their overall prevalence of specific HPV types in ICC versus HG-CIN, their age-specific 
prevalence in ICC and HG-CIN reflects another distinguishing aspect of HPV16/18/45-related cervical 
lesions compared to lesions infected with other HPV types. This analysis performed new datas in 
European population. ICC associated with HPV16/18/45 tended to be diagnosed at an earlier age than 
ICC related to ‘other’ HPV types. This, together with the above findings, reinforces the hypothesis that 
HPV16/18/45 may have a greater potential for rapid neoplastic transformation than other types as 
found in other studies. The results confirm the later presentation of HPV18- and HPV45-related CIN3 
and the narrow age range between the detection of HPV18- and HPV45-related CIN3 and HPV18- 
and HPV45-related ICC. It was also notable that the study identified no cases of HPV45-related AIS 
despite identifying several cases of HPV45-related ADC. These observations are consistent with data 
on HPV type specific integration suggesting that HPV18 and HPV45 may promote a higher degree of 
chromosomal instability than other types.  
 
Our observations on the prevalence ratios and differences in median age at diagnosis for HG-CIN and 
ICC associated with HPV18/45/39 – which are all of the same alpha-7 clade – also suggest that this 
group of HPV types may have a distinct natural history different from that of HPV16 or other HPV 
types. HPV16 predominates in both HG-CIN and ICC, especially in SCC. HPV types of the alpha-7 
clade (18/39/45) are much more prevalent in ICC than in HG-CIN, being relatively infrequent in the 
latter. In comparison, HPV31 and HPV33 have a large median age difference between HG-CIN and 
ICC, and are more prevalent in HG-CIN than in ICC.  
The strengths of the present studies include the large number of subjects and the diversity of selected 
European countries with and without screening programmes, to which a standardised study protocol 
was applied. Pooled data analysis allowed the inclusion of a large sample size and a wide 
geographical coverage across Europe whilst controlling for possible discrepancies and biases 
between the countries and study populations (e.g. differing geographical HPV type distribution, 
variations in cervical cancer screening policies and methods, etc.). The study design did not include a 
normal control population and was cross-sectional so that any consideration of actual progression 
from HG-CIN to ICC for individual HPV types remains hypothetical. However, our findings provide 
important information regarding differences in the prevalence of the individual HPV types in ICC 
versus HG-CIN, and differences in median age of diagnosis of lesions associated with individual HR-
HPV types. Estimates of the prevalence of infrequent HPV types and results on rarer histological 
diagnoses (e.g., AIS) are limited by number of cases and resulting wide confidence intervals. This 
resulted from consistent, expert central pathology review being able to exclude cases of CIN1 that had 
been erroneously submitted. 
As in other clinical trial the histological diagnosis of CIN1 cases has also chosen the follow-up 
regardless of the status of the surgical margins.  In recent years, several studies have dealt with the 
development of precancerous risk factors. Positive correlation was found between the surgical margin, 
HPV positive after treatment and the remaining histological differences. In our clinical study  the 
patients referred to second conisation because of positive surgical margins were taken HPV DNA 
status before second conisation proved to be a good predictive factor of potentially precancerous 
residual image. 
In our clinical study, we in addition to HPV DNA positivity is confirmed in the remaining histological 
differences, it has also been shown that the type specific HPV DNA detection is good  in the definition 
of the degree of severity. 
This observation correlates well with the our European, large epidemiological  analysis, wherein the 
type specific HPV  caused by the progression of pre-malignant condition could be monitored.  
It is also in  the second study, we were able to demonstrate that in case of repeated HPV test 
negativity we did not find any residual severe histologic abnormalities.  This observation is a significant 
step forward in the positive surgical margins cases on the choice of a treatment strategy. The 
reconisation has had significant risk for miscarriage and premature births respectively.  
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 In our study we demonstrated that the sensitivity of the second (pre-reconisation)  HPV test is 94%to 
predict severe residual dysplasia. The negative predictive value of the second HPV test for prediction 
of severe residual dysplasia has been 100%. 
According to the age distribution, in contrast to other authors, we were unable to distinguish between 
the under or over 35 year. We could not find the older age as a pathognomonic factor for prediction of 
the residual dysplasia. 
 In conclusion, we can say that in all cases where the positive surgical margins was occured at the 
conisation, the first and the second ( pre-reconisation) HPV DNA test result comparison crucially 
affects another indication of conisation.  Only  those cases suggested the re-conisation where the 
high-risk HPV infection is identified at the second HPV test. It has been obviously demonstrated  if  
HR-HPV DNA has  not been detected at the second HPV DNA test, it is not recommended to perform 
re-conisation because of no chance of the severe residual cervical dysplasia. The experience gained 
from our observation, helping every practicing gynecologist, it is important to note that all patients 
treated for HG CIN must be carefully followed up for at least 10 years because a British study revealed 
that the risk of developing an invasive cevical cancer among these women during the next  8 years is 
about five times higher than that of the general population. 
In our clinical investigations have shown that the pre-cancerous conditions (CIN2 / 3) was detected in  
child-bearing age so we feel it essential that the indication of the conisation and aleatory re-conisation 
should be determined by strict criteria. 
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4. Ésik O., Koiss R., Kneffel P., et al.: Műtét előtti, kizárólagos üregi sugárkezelés méhnyak-és 
méhtestrákos kórképekben:bizonyítékok és nemzetközi szakértői vélemények .Nőgyógyászati 
Onkológia 2005;10:168-172 
5. Koiss R.: Méhnyakrák elleni védőoltás. Praxis, 2006. 15 évf.6.szám: 65-67 
6. Koiss R.: A méhnyakrák megelőzésének új lehetősége vakcinációval. Infektológia és Klinikai 
Mikrobiológia XIII. évf 1.suppl. 2006. október  
7. Koiss R.: HPV és a méhnyakrák kapcsolata. Hippocrates. 2007;9:47-50. 
8. Koiss R.:  A méhnyakrák elleni védőoltással kapcsolatos  gyakorlati kérdések MAGYAR 
BELORVOSI ARCHÍVUM Supplementum 2008/2.  45-47. 
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9. Koiss R.: A méhnyakrák és a száj-,garatrákokgyakorisága a HPV-fertőzés 
tükrében.Nőgyógyászati Onkológia 2008;13:135-137 
10. Patyánik M,.Nemeskéri C, Póti Z, Sinkó D, Pesznyák C, Király R, Koiss R, Mayer 
A.:Concomitant radiochemotherapy of cervical cancer: is it justified to reduce the dosage of 
cisplatin? Strahlenther Onkol. 2009 Sep;185(9):582-7. Epub 2009 Sep 12  IF: 3.776  
Hivatkozás: 5 
11. Koiss R., Siklós P.: A HPV és a méhnyakrák kapcsolata. LAM, 2010;20(2):96-102  
12. Horányi D.,Koiss R.,Babarczi E.,Siklós P.,:Az őrszemnyirokcsomó eltávolításával szerzett 
tapasztalataink a szeméremtest rosszindulatú daganatainak kezelése során. Magyar 
Nőorvosok Lapja 2011;74 (2) pp. 34-37  
13. Horányi D.,Koiss R., Babarczi E.,Siklós P.: A petefészek ivarléc-stroma eredetű daganatinak 
kezelésével szerzett tapasztalataink. Nőgyógyászati Onkológia 2011;16:40-42 
14. Koiss R.: Méhnyakrák prevenció a XXI.században: védőoltás és/vagy szűrés? Medicus 
Universalis  44: (4)pp. 163-165, 2011. 
15. Koiss R.: A HPV-teszt fordulópontot jelent a méhnyakrákszűrésében.  Nőgyógyászati és 
Szülészeti Továbbképző Szemle, 13:(5) pp. 199-201, 2011.  
16. Gőcze P., Koiss R., A méhnyakrákszűrés és a HPV-védőoltás helyzete Magyaroszágon.  
Nőgyógyászati és Szülészeti Továbbképző Szemle 13:(5) pp. 204-207. 2011 
17. R. Koiss, E. Babarczi , Cs.Jenei, P. Gőcze, D.Horányi, P. Siklós,: Repeat conisation or  HPV 
test? What should be done if  histology of the primary conisation requires second conisation ?  
Eur. J.Gynaecol. Oncol. 2012;33(2):134-7 IF:0.633 
18. Tjalma WA, Fiander A, Reich O, Powell N, Nowakowski AM, Kirschner B, Koiss R, O'Leary J, 
Joura EA, Rosenlund M, Colau B, Schledermann D, Kukk K, Damaskou V, Repanti M, 
Vladareanu R, Kolomiets L, Savicheva A, Shipitsyna E, Ordi J, Molijn A, Quint W, Raillard A, 
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Announcements- Abstracts: 
1. Marek E., Gőcze P., Bózsa
 
Sz., Molnár
 
G., Stefanovits
 
Á., Benczik
 
M., Koiss
 
R.,Gőcze
 
K., 
Survey of knowledge about the HPV infection and cervical cancer among students and 
parents in Hungary,Poster in Bridges in Life Sciences US –CEE Regional Networking Meeting 
IV April 4, 2009 Debrecen, Hungary 
2. Marek E., Gőcze P, Bózsa Sz, Molnár G.,Stefanovits Á, Benczik M, Koiss R, Gőcze K: 
Survey of knowledge about HPV infection in Hungary.  Poster The 25th International 
Papillomavirus Conference,May 8-14 2009, Malmö, Sweden. 
3. C.Jeney;C.Józsa;N.Varga;A.Kovács;J.Mózes;R.Koiss: „Evalutaion of a new screening 
biomarker panel”- Poster The 25th International Papillomavirus Conference May 8-14, 2009, 
Malmö, Sweden 
4. C.Jeney;C.Józsa;N.Varga; M.Benczik J.Mózes; R.Koiss: „Detection and evaluation of a new 
screening biomarker panel” Poster,The 26 th IPV Conference, July 05-08, 2010 
Montreal,Canada 
5. R.Koiss T.Wiebren; A.Fiander; O. Reich; B. Kirschner;„ Human papillomavirus type 
distribution in women with high-grade cervical intraepithelial neoplasia and invasive cervical 
cancer in Europa” Poster, The13th biennal meeting of the IGCS, okt. 23-27, 2010 Prague, 
Czech Republic  
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6. Koiss R, Babarczi E, Jeney C,Gőcze P.Horányi L,Siklós P: Reconisation or repeated HPV 
test?  P6-21 EUROGIN 2011 Lisbon Portugal, 8-11., May, 2011 
Chapter in book:  
Robert Koiss (2012). Screening Methods in Prevention of Cervical Cancer, Human Papillomavirus 
and Related Diseases - From Bench to Bedside - A Clinical Perspective, Davy Vanden Broeck (Ed.), 
ISBN:978-953-307-860-1,InTech,Availablefrom: 
http://www.intechopen.com/articles/show/title/screening-methods-in-prevention-of-cervical-cancer 
My lectures:  
My lecture in English on this topic: 
R.Koiss: “ Is there any importance of the detection of “high-risk” HPV types in a gynecology cervical 
screening program ?’ Congress of Hungarian Society for Microbiology 08. 2000.Hungary  
R.Koiss: ”Prevention of ovarian cancer.”.EAGC and III. Congress of Hungarian Assosiation of 
Gynecologic Oncology, 11. 2001 Hungary 
R Koiss:. “ Occurance of “ high-risk”  HPV types in the specimens of the conisation of patient suffering 
CIN”. XI. Congress of EAGO, 09.2001. Hungary 
R Koiss:  ”What should we do, if the result of the histology indicates reconisation?” X.International 
Workshop on lower genital pathology and HPV disease 2010.05.07. Viareggio, Italy 
R.Koiss, Babarczi E, Jeney Cs, Gőcze P, Horányi D, Siklós P.: „Reconisation or repeated HPV test? 
What should we do if the histology of the primary conisation requires reconisation? „ 1st EAGC-ESO 
Congress, 16.May 2010. Hungary 
 
 
My lectures in Hungarian on this topic: 
Koiss R.: „A HPV kimutatás jelentősége napjainkban.”  Magyar Kolposzkópos és Méhnyakkórtani 
Társaság Első Nagygyűlése (2004.11.26. Budapest) 
Koiss R.: „ A méhnyakrák megelőzése védőoltással.” Szegedi Tudományegyetem ÁOK Családorvosi 
Tanszék Kötelező Szintentartó Tanfolyam (2006.09.23. Szeged) 
Koiss R.: „Amire a természet nem volt képes, avagy hogyan véd a HPV elleni védőoltás.” VIII. 
Antibiotikum Továbbképző Szimpózium (2007.05.10-11 Miskolc) 
Koiss R.: „Mit tehetünk a vírusfertőzések megelőzése érdekében, különös tekintettel a HPV 
infekcióra?” SZTE ÁOK  27. Consilium trimestre (2007.09.28. Szeged) 
Koiss R.: „A méhnyakrák megelőzésének új generációja, avagy HPV elleni vakcináció.” Magyar 
Nőorvos Társaság Dél-Magyarországi és Közép-Magyarországi Szekciójának közös Kongresszusa 
(2007.10.12-13. Kecskemét) 
Koiss R.: „Cervarix: hosszútávú védettség a méhnyakrák ellen.” XI.Budapesti Gyermekgyógyászati 
Továbbképző Tanfolyam (2008.03.07-08. Budapest) 
Koiss R.: „A HPV elleni vakcináció gyakorlati kérdései.” Magyar Nőorvos Társaság 
Gyermeknőgyógyász Szekció XXVIII.Kongresszusa (2008.04.18-19 Debrecen) 
Koiss R.: „Cervarix: Hosszútávú, biztos védettség a méhnyakrák ellen.” Magyar Gyermekorvos 
Társaság 52. Nagygyűlése (2008.04.24-26 Szeged) 
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Koiss R.: „ Hogyan bizosíthatunk hosszútávú, biztos védettséget a méhnyakrák ellen?” Házi 
Gyermekorvosok Egyesülete X. Tudományos Konferencia (2008.05.23-25 Siófok)  
Koiss R.: „Kérdések és válaszok a Cervarix, méhnyakrák elleni vakcinával kapcsolatban.” Magyar 
Gyermekorvosok Társasága Északnyugat-Magyarországi 59. Tudományos Ülése (2008.06.06-07. 
Tata) 
Koiss R.: „ A rák megelőzése védőoltással:méhnyakrák.” III. Belgyógyászati Kötelező Szintentartó 
Tanfolyam ( 2008.10.01-04. Budapest) 
Koiss R.: „Kérdések és válaszok a méhnyakrák megelőzéssel kapcsolatban.” Magyar Nőorvos 
Társaság Délkelet-Magyarországi Szekciójának XXIX.Kongresszusa (2008.10.10-12. Orosháza) 
Koiss R.: „ Fogamzásgátlás tinédzserkorban” Hitek és Tévhitek IX. Továbbképző Tanfolyam 
(2008.11.20-22. Tapolca) 
Koiss R.: „ A szisztémás és lokális ellenanyagok szerepe a HPV elleni hosszútávú védettség 
kialakításában.” Magyar STD Társaság XIII.Nagygyűlése és a II. Venerológiai Továbbképző 
Tanfolyam (2008.11.20-22. Budapest) 
Koiss R.: „Az immunitás jelentősége a védőoltás hatékonyságában.”  Magyar Méhnyakkórtani és 
Kolposzkópos Társaság II. Nagygyűlése (2009.03.13. Budapest) 
Koiss R.: „Cervarix: biztonságos és hatékony védelem a méhnyakrák ellen.” XII. Budapesti 
Gyermekgyógyászati Továbbképző Tanfolyam (2009.03.20-21. Budapest) 
Koiss R.: „ Méhnyakrák elleni vakcináció a szexuálisan aktív kamaszkorban.” XV. Országos 
Védőoltási Továbbképző Tanfolyam (2009.05.24-25. Eger) 
Koiss R.: „A méhnyakrák elleni vakcináció legfrissebb kutatási eredményei.” Házi Gyermekorvosok 
Egyesülete XI. Tudományos Konferencia (2009.05.22-24. Siófok)  
Koiss R.: „ HPV, méhnyakrák, idősebb életkor.” Magyar Menopausa Társaság VIII.Országos 
Kongresszus (2009.06.12-13. Balatonalmádi) 
Koiss R.: „ A sikeres méhnyakrák elleni oltás titka.” Hitek és Tévhitek X. Továbbképző Tanfolyam 
(2009.11.12-14. Velence) 
Koiss R. Babarczi E.  Jenei Cs. Gőcze P. Siklós N. Siklós P.: „ A HPV törzsek megoszlása a 
cervicalis dysplasiák súlyossága szempontjából.” Magyar Nőorvos Társaság XXIX. Nagygyűlése 
(2010.05.20-22. Debrecen) 
Koiss R., Babarczi E.Jenei Cs. Gőcze P. Horányi D. Siklós P.: „ Hurokkimetszés-vagy HPV teszt ? Mit 
tegyünk, ha a hurokkimetszés szövettani értékelése újabb műtétet kívánna?” Magyar Nőorvos 
Társaság XXIX. Nagygyűlése (2010.05.20-22. Debrecen) 
Koiss R.:  „Tapasztalatok a méhnyakrák elleni vakcinációval kapcsolatban.” Magyar Nőorvos 
Társaság XXIX. Nagygyűlése (2010.05.20-22. Debrecen),  
Koiss R.:  „ A HPV, mint elsődleges szűrővizsgálat eljárás a méhnyakrák szűrésben.” Magyar 
Nőgyógyász Onkológus Társaság VIII. Kongresszusa (2011.11.11. Debrecen) 
Koiss R.: „ A HPV-DNS, mint elsődleges szűrővizsgálat eljárás a méhnyakrák szűrésben.” Magyar 
Méhnyakkórtani és Kolposzkópos Társaság III. Nagygyűlése (2012.10.12. Salgótarján) 
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